title: Country breakout session highlights.
abstract: At the 2016 MS Experts Summit, country-relevant aspects pertaining to the management of symptoms and disability in multiple sclerosis (MS), with emphasis on those associated with spasticity, were explored in interactive country breakout sessions chaired by selected MS experts. Attendees had the opportunity to review and discuss topics in their own native language. After feedback from each session leader, key messages were collated and presented in a Plenary Session by Summit chair, Professor Angelo Ghezzi. Topics at this year's Summit included: gait tracking (Germany/Switzerland); the Care Alliance against MS spasticity (Italy); MS spasticity and associated symptoms (France); improvement in MS symptoms and functionality and patients' independence (Spain); Swedish MS guidelines (Sweden/Rest of World).
authors.affiliation: Neurologia 2, Centro Studi Sclerosi Multipla, Gallarate Hospital, Gallarate, Italy.
authors.forename: Angelo
authors.initials: A
authors.lastname: Ghezzi
authors.affiliation: Gait Research Laboratory, Department of Neurology, University Hospital Zurich, Zurich, Switzerland.
authors.forename: Linard
authors.initials: L
authors.lastname: Filli
authors.affiliation: Neurology Unit, Head & Neck Department, ASL 3 'Genovese', Genova, Italy.
authors.forename: Claudio
authors.initials: C
authors.lastname: Solaro
authors.affiliation: Clinique du Parc, Clinique des Cèdres, Toulouse, France.
authors.forename: Claude
authors.initials: C
authors.lastname: Mekies
authors.affiliation: Neurology Department, Hospital Universitario Dr. Peset, Valencia, Spain.
authors.forename: Lamberto
authors.initials: L
authors.lastname: Landete
authors.affiliation: Department of Clinical Neuroscience, Institute of Neuroscience & Physiology at Sahlgrenska Academy, University of Gothenburg & Sahlgrenska University Hospital, Gothenburg, Sweden.
authors.forename: Jan
authors.initials: J
authors.lastname: Lycke
mesh_terms: D002185:Cannabidiol / Q000627:therapeutic use; D013759:Dronabinol / Q000627:therapeutic use; D004338:Drug Combinations; D005060:Europe; D020233:Gait Disorders, Neurologic / Q000209:etiology / Q000628:therapy; D006801:Humans; D009103:Multiple Sclerosis / Q000150:complications / Q000628:therapy*; D009128:Muscle Spasticity / Q000209:etiology / Q000628:therapy
chemical_list: D004338:Drug Combinations; D002185:Cannabidiol; D013759:Dronabinol; C587251:nabiximols
keywords: gait tracking; guidelines; multiple sclerosis; rehabilitation; symptom management